Drug profile · INN
ethosuximide
ZARONTIN
ethosuximide (ZARONTIN) is a voltage-gated t-type calcium channel blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — ethosuximide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
ethosuximide (ZARONTIN) is a voltage-gated t-type calcium channel blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Voltage-gated T-type calcium channel blocker
Primary target: Voltage-gated T-type calcium channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ethosuximide?
ethosuximide (ZARONTIN) is a voltage-gated t-type calcium channel blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ethosuximide?
ZARONTIN is a marketed brand name for ethosuximide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ethosuximide?
ethosuximide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.